Cited 11 times in
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤동섭 | - |
dc.contributor.author | 이동기 | - |
dc.contributor.author | 이세준 | - |
dc.contributor.author | 임재윤 | - |
dc.contributor.author | 정희철 | - |
dc.contributor.author | 조재용 | - |
dc.contributor.author | 문희선 | - |
dc.contributor.author | 백용한 | - |
dc.date.accessioned | 2015-05-19T17:41:26Z | - |
dc.date.available | 2015-05-19T17:41:26Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0959-4973 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/108629 | - |
dc.description.abstract | Biliary tract carcinoma is often diagnosed at an advanced stage, and there is currently no established palliative standard of care. This phase II study investigated the efficacy and safety of combination chemotherapy of oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) in biliary tract carcinoma. Patients with unresectable or recurrent biliary tract carcinoma were enrolled, including pretreated and chemotherapy-naive patients. Treatment consisted of intravenous oxaliplatin (100 mg/m2, day 1) followed by leucovorin (100 mg/m2, day 1) and 5-FU (1000 mg/m2, days 1 and 2). Treatment was repeated every 3 weeks. The efficacy and safety of the treatment were determined. Twenty-eight patients were evaluable, and a total of 166 cycles were administered (median five cycles). One complete response (3.6%) and five partial responses (17.9%) were noted, with a response rate of 21.5% [95% confidence interval (CI): 6.2-36.7], according to Response Evaluation Criteria in Solid Tumors criteria. The median time to progression and overall survival was 3.5 months (95% CI: 2.7-4.3) and 10.0 months (95% CI: 7.2-12.8), respectively. The 1-year survival rate was 17.8%. Grade 3/4 neutropenia and thrombocytopenia were recorded in 18 and 4% of the patients, respectively. No treatment-related death was observed. Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 631~635 | - |
dc.relation.isPartOf | ANTI-CANCER DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Biliary Tract Neoplasms/drug therapy* | - |
dc.subject.MESH | Biliary Tract Neoplasms/mortality | - |
dc.subject.MESH | Biliary Tract Neoplasms/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/mortality | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Oxaliplatin | - |
dc.title | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae Yun Lim | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.contributor.googleauthor | Hee Sun Mun | - |
dc.contributor.googleauthor | Dong Ki Lee | - |
dc.contributor.googleauthor | Yong Han Paik | - |
dc.contributor.googleauthor | Se Joon Lee | - |
dc.contributor.googleauthor | Dong Sup Yoon | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.identifier.doi | 10.1097/CAD.0b013e3283017f94 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02548 | - |
dc.contributor.localId | A02723 | - |
dc.contributor.localId | A02882 | - |
dc.contributor.localId | A03398 | - |
dc.contributor.localId | A03899 | - |
dc.contributor.localId | A01396 | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J00187 | - |
dc.identifier.eissn | 1473-5741 | - |
dc.identifier.pmid | 18525323 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00001813-200807000-00010&LSLINK=80&D=ovft | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Biliary Tract Neoplasms/drug therapy* | - |
dc.subject.keyword | Biliary Tract Neoplasms/mortality | - |
dc.subject.keyword | Biliary Tract Neoplasms/pathology | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Fluorouracil/administration & dosage | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Leucovorin/administration & dosage | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Neoplasm Metastasis | - |
dc.subject.keyword | Neoplasm Recurrence, Local/drug therapy* | - |
dc.subject.keyword | Neoplasm Recurrence, Local/mortality | - |
dc.subject.keyword | Organoplatinum Compounds/administration & dosage | - |
dc.subject.keyword | Oxaliplatin | - |
dc.contributor.alternativeName | Yoon, Dong Sup | - |
dc.contributor.alternativeName | Lee, Dong Ki | - |
dc.contributor.alternativeName | Lee, Se Joon | - |
dc.contributor.alternativeName | Lim, Jae Yun | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.alternativeName | Mun, Hee Sun | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | Yoon, Dong Sup | - |
dc.contributor.affiliatedAuthor | Lee, Dong Ki | - |
dc.contributor.affiliatedAuthor | Lee, Se Joon | - |
dc.contributor.affiliatedAuthor | Lim, Jae Yun | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Mun, Hee Sun | - |
dc.contributor.affiliatedAuthor | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 19 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 631 | - |
dc.citation.endPage | 635 | - |
dc.identifier.bibliographicCitation | ANTI-CANCER DRUGS, Vol.19(6) : 631-635, 2008 | - |
dc.identifier.rimsid | 37141 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.